Treatment Study for Patients with Lymphoma or Solid Tumor Malignancies

Clinical Trial Title

Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy in Patients with Lymphoma or Solid Tumor Malignancies

National Clinical Trial Number:

NCT03884556

Clinical Trial Protocol Description:

The purpose of this study is to what the highest dose of TTX-030 that can be given to subjects when given as an intravenous (IV – through a needle into your vein) over a 30 minute period once every 2 or 4 weeks (for Arm 1), once every 3 weeks (for Arms 1-3) or once every 2 weeks (for Arm 4). This study is also looking to determine the side effects of TTX-030 when given alone or in combination with either of the commercially approved agents and to determine how much TTX-030 is in the blood at specific times after dosing and how does the body get rid of the TTX-030.

If you agree to participate in this study, your participation may last up to 3 years and you will be asked to complete 14 or more study visits.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are 18 years of age or older.
  • Are willing and able to provide informed consent.
  • Are able to provide a fresh or archived tumor tissue.
  • Have evidence of measurable disease by CT or MRI.
  • Have demonstrated adequate organ function.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Alan Tan, MD

Contact Information

Rush Cancer Center Clinical Trials Office